## Gestational Trophoblastic Neoplasia: Chemotherapy Selection ### Risk Stratification This patient has **high-risk GTN** based on: - β-hCG >100,000 mIU/mL - Brain and lung metastases (FIGO score ≥8) - Interval >4 months from antecedent pregnancy **Key Point:** High-risk GTN requires multiagent chemotherapy; single-agent methotrexate is inadequate and will result in treatment failure. ### EMA-CO Regimen: First-Line for High-Risk GTN | Component | Agent | Purpose | |-----------|-------|----------| | **E** | Etoposide | Topoisomerase II inhibitor | | **M** | Methotrexate | Antimetabolite | | **A** | Actinomycin D | Intercalating agent | | **C** | Cyclophosphamide | Alkylating agent | | **O** | Vincristine (Oncovin) | Microtubule inhibitor | **High-Yield:** EMA-CO achieves cure rates >90% in high-risk GTN, even with brain metastases. It is the gold standard first-line regimen endorsed by FIGO, ASCO, and most international guidelines. ### Clinical Pearl Brain metastases in GTN are **chemosensitive** — EMA-CO penetrates the CNS adequately (especially with high-dose methotrexate) and does not require cranial radiation or surgery in most cases. Patients with brain involvement still achieve excellent outcomes with EMA-CO alone. **Mnemonic:** **EMA-CO = "Every Metastatic Aggressive" case needs this regimen** — think of it as the heavyweight chemotherapy for the most aggressive trophoblastic tumours. ### Why Single-Agent Methotrexate Fails in High-Risk Disease Methotrexate monotherapy is reserved for **low-risk GTN** (FIGO score <7, β-hCG <100,000). In high-risk disease, single-agent therapy has cure rates <50% and is considered inadequate.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.